On August 22nd, Novo Nordisk announced that European health regulators have approved the use of Fiasp, a rapid-acting insulin, for children and adolescents with type 1 diabetes. The insulin now is approved for all patients with type 1 diabetes, ages 1 and above, in the European Union.
In the United States, the FDA first approved Fiasp for adults with type 1 diabetes in 2017. In March 2019, Novo Nordisk asked for expanded FDA approval for Fiasp for children with type 1 diabetes. The FDA has not yet delivered a decision on that request.
Fiasp has been engineered with Vitamin B3 to allow for more rapid absorption into the bloodstream than occurs with other injectable insulin aspart brands on the market. The rapid absorption can lead to better post-meal blood sugar levels; however, researchers have noted that this has not, in turn, led to better overall blood sugar levels among Fiasp users.